Poster
T-DXd
ASCO GI 2025 | January 23-25, 2025
Gastric Cancer
Concordance between HER2 status by IHC and NGS in tissue and blood samples from gastric and gastroesophageal junction cancers
Steven B. Maron
Poster
HER3-DXd
ASCO GI 2025 | January 23-25, 2025
Gastric Cancer
Phase 1/2 study of the HER3-directed antibody-drug conjugate patritumab deruxtecan (MK-1022) as monotherapy in patients with gastrointestinal cancers
Do-Youn Oh
Poster
T-DXd
ASCO GI 2025 | January 23-25, 2025
Gastric Cancer
Real-world safety of trastuzumab deruxtecan with gastric cancer: All-patient post-marketing surveillance study in Japan
Hisato Kawakami
Poster
T-DXd
ASCO GI 2025 | January 23-25, 2025
Gastric Cancer
Updated results from the trastuzumab deruxtecan 5.4 mg/kg triplet combination of DESTINY-Gastric03: First-line T-DXd with fluoropyrimidine and pembrolizumab in advanced or metastatic HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma
Yelena Y. Janjigian
Poster
T-DXd, Valemetostat
ASCO GI 2025 | January 23-25, 2025
Gastric Cancer
Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated, advanced, or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma
Kohei Shitara